We further demonstrated a significant increase of all IL-17 isoforms tested in BP blister fluid compared with BP serum (IL-17A, <i>p</i> < 0.0001; IL-17A/F, <i>p</i> < 0.0001; IL-17B, <i>p</i> = 0.0023; IL-17C, <i>p</i> = 0.0022; IL-17E, <i>p</i> < 0.0001).
Our data give evidence for a pivotal role of IL-17A in the pathophysiology of BP and advocate IL-17A inhibition as potential novel treatment for this disease.
<b>Objective:</b> We sought to assess whether ETs were associated with BP as well as the relative contribution of IL-17 axis cytokines to NET induction.
The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release from infiltrated inflammatory cells.